Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 9956 results found since Jan 2013.
Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer
CONCLUSIONS: Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.PMID:37609671 | DOI:10.1093/jjco/hyad112
Source: Clinical Breast Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Akiko Matsumoto Hiromitsu Jinno Saki Naruse Yuka Isono Yuka Maeda Ayana Sato Miki Yamada Tatsuhiko Ikeda Yuko Sasajima Source Type: research
The Role of MRI in Assessing Residual Breast Cancer After Neoadjuvant Chemotherapy
CONCLUSION: Magnetic resonance imaging is a good test to assess the residual tumor disease after NAC in breast cancer patients. However, cases of under- and overestimation are still seen, which require more caution when making a decision regarding the management of such cases.PMID:37611928 | DOI:10.1177/00031348231198108
Source: The American Surgeon - August 23, 2023 Category: Surgery Authors: Emad Rezkallah Kamel Mekhaeil Su Min Min Tin Ragai Sobhy Hanna Source Type: research
ASO Author Reflections: Targeted Therapy Combined with Immunotherapy as Neoadjuvant Treatment for Locally Advanced Differentiated Thyroid Cancer
Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14063-5. Online ahead of print.NO ABSTRACTPMID:37612548 | DOI:10.1245/s10434-023-14063-5
Source: Ann Oncol - August 23, 2023 Category: Cancer & Oncology Authors: Jia-Ying Chen Yu-Long Wang Yu Wang Qing-Hai Ji Source Type: research
Primary breast angiosarcoma in a postmenopausal woman: A case report
CONCLUSION: Breast primary angiosarcoma is a rare entity in post-menopausal women that should be considered in the differentials of breast lumps. Standardized information is limited though current management includes local control with radical surgery. The role for neoadjuvant therapy, adjuvant radiotherapy or chemotherapy is still unclear.PMID:37611400 | DOI:10.1016/j.ijscr.2023.108700
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Callie Killoran Thushara Dissanayake Source Type: research
Surgical Management of the Axilla in HR+/HER2- Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
CONCLUSION: The final surgical management strategy used for cN1, HR+/HER2- IDC patients who achieved a cCR to NAST did not have a significant impact on survival outcomes in this analysis. Potential opportunities for de-escalation of axillary management among this patient subset exist, and validation studies are needed.PMID:37610487 | DOI:10.1245/s10434-023-14029-7
Source: Ann Oncol - August 23, 2023 Category: Cancer & Oncology Authors: Vayda R Barker Samer A Naffouje Melissa A Mallory Susan A Hoover Christine Laronga Source Type: research
The Role of MRI in Assessing Residual Breast Cancer After Neoadjuvant Chemotherapy
CONCLUSION: Magnetic resonance imaging is a good test to assess the residual tumor disease after NAC in breast cancer patients. However, cases of under- and overestimation are still seen, which require more caution when making a decision regarding the management of such cases.PMID:37611928 | DOI:10.1177/00031348231198108
Source: The American Surgeon - August 23, 2023 Category: Surgery Authors: Emad Rezkallah Kamel Mekhaeil Su Min Min Tin Ragai Sobhy Hanna Source Type: research
ASO Author Reflections: Targeted Therapy Combined with Immunotherapy as Neoadjuvant Treatment for Locally Advanced Differentiated Thyroid Cancer
Ann Surg Oncol. 2023 Aug 23. doi: 10.1245/s10434-023-14063-5. Online ahead of print.NO ABSTRACTPMID:37612548 | DOI:10.1245/s10434-023-14063-5
Source: Ann Oncol - August 23, 2023 Category: Cancer & Oncology Authors: Jia-Ying Chen Yu-Long Wang Yu Wang Qing-Hai Ji Source Type: research
Surgical Management of the Axilla in HR+/HER2- Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
CONCLUSION: The final surgical management strategy used for cN1, HR+/HER2- IDC patients who achieved a cCR to NAST did not have a significant impact on survival outcomes in this analysis. Potential opportunities for de-escalation of axillary management among this patient subset exist, and validation studies are needed.PMID:37610487 | DOI:10.1245/s10434-023-14029-7
Source: Ann Oncol - August 23, 2023 Category: Cancer & Oncology Authors: Vayda R Barker Samer A Naffouje Melissa A Mallory Susan A Hoover Christine Laronga Source Type: research
Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer
CONCLUSIONS: Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.PMID:37609671 | DOI:10.1093/jjco/hyad112
Source: Clinical Genitourinary Cancer - August 23, 2023 Category: Cancer & Oncology Authors: Akiko Matsumoto Hiromitsu Jinno Saki Naruse Yuka Isono Yuka Maeda Ayana Sato Miki Yamada Tatsuhiko Ikeda Yuko Sasajima Source Type: research
Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy
CONCLUSIONS: Discordance between breast and axillary pCR is not infrequent and may be related to a number of patient-related factors and tumor characteristics impacting nodal response to NAC. Further investigation into differing responses to NAC is warranted to better understand the mechanism of this phenomenon and to determine how these findings may influence treatment.PMID:37606840 | DOI:10.1245/s10434-023-14082-2
Source: Ann Oncol - August 22, 2023 Category: Cancer & Oncology Authors: Rene Flores Estefania Roldan Jaime A Pardo Leah Beight Jessalyn Ubellacker Betty Fan Roger B Davis Ted A James Source Type: research
Intraoperative Ultrasound-Guided Conserving Surgery for Breast Cancer: No More Time for Blind Surgery
CONCLUSIONS: IOUS allows real-time resection margin visualization and continuous control during BCS. It showed clear superiority over TS in both oncological and surgical outcomes for all breast cancer lesion types. These results disfavor the paradigm of blind breast surgery.PMID:37606837 | DOI:10.1245/s10434-023-13900-x
Source: Ann Oncol - August 22, 2023 Category: Cancer & Oncology Authors: Massimo Ferrucci Francesco Milardi Daniele Passeri Luaya Fabrizio Mpungu Andrea Francavilla Matteo Cagol Tania Saibene Silvia Michieletto Mariacristina Toffanin Paola Del Bianco Ugo Grossi Alberto Marchet Source Type: research
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
CONCLUSION: Previous viral, bacterial and protozoal neurotropic infections appear not to be associated with the development of neurological irAEs in melanoma patients who underwent therapy with ICI across 3 countries. Further efforts are needed to unravel the factors underlying neurological irAEs in order to identify risk factors for these toxicities, especially with the increasing use of ICI in earlier stage disease.PMID:37606856 | DOI:10.1007/s00262-023-03498-0
Source: Herpes - August 22, 2023 Category: Infectious Diseases Authors: C Schmitt E P Hoefsmit T Fangmeier N Kramer C Kabakci J Vera Gonz ález J M Versluis A Compter T Harrer H Mijo čević S Schubert T Hundsberger A M Menzies R A Scolyer G V Long L E French C U Blank L M Heinzerling Source Type: research
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis
CONCLUSIONS: This meta-analysis provides preliminary evidence of the efficacy and safety of neoadjuvant immunotherapy for HCC, suggesting that it is a promising perioperative treatment option. Conclusive evidence supporting its use requires additional data from large-scale clinical trials.PMID:37606124 | DOI:10.26355/eurrev_202308_33287
Source: Pharmacological Reviews - August 22, 2023 Category: Drugs & Pharmacology Authors: Y-H Han J-Q Bo L-X Liu Source Type: research
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
CONCLUSION: Previous viral, bacterial and protozoal neurotropic infections appear not to be associated with the development of neurological irAEs in melanoma patients who underwent therapy with ICI across 3 countries. Further efforts are needed to unravel the factors underlying neurological irAEs in order to identify risk factors for these toxicities, especially with the increasing use of ICI in earlier stage disease.PMID:37606856 | DOI:10.1007/s00262-023-03498-0
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: C Schmitt E P Hoefsmit T Fangmeier N Kramer C Kabakci J Vera Gonz ález J M Versluis A Compter T Harrer H Mijo čević S Schubert T Hundsberger A M Menzies R A Scolyer G V Long L E French C U Blank L M Heinzerling Source Type: research
Intraoperative Ultrasound-Guided Conserving Surgery for Breast Cancer: No More Time for Blind Surgery
CONCLUSIONS: IOUS allows real-time resection margin visualization and continuous control during BCS. It showed clear superiority over TS in both oncological and surgical outcomes for all breast cancer lesion types. These results disfavor the paradigm of blind breast surgery.PMID:37606837 | DOI:10.1245/s10434-023-13900-x
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Massimo Ferrucci Francesco Milardi Daniele Passeri Luaya Fabrizio Mpungu Andrea Francavilla Matteo Cagol Tania Saibene Silvia Michieletto Mariacristina Toffanin Paola Del Bianco Ugo Grossi Alberto Marchet Source Type: research
